Enanta Pharmaceuticals Inc financial data

Symbol
ENTA on Nasdaq
Industry
Pharmaceutical Preparations
Location
500 Arsenal Street, Watertown, MA
State of incorporation
DE
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2024 - Aug 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 609 % -29%
Debt-to-equity 135 % +268%
Return On Equity -63.8 % -36.3%
Return On Assets -27.1 % +20.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 21.2M shares +0.63%
Common Stock, Shares, Outstanding 21.2M shares +0.6%
Entity Public Float 800M USD -36.6%
Common Stock, Value, Issued 212K USD +0.95%
Weighted Average Number of Shares Outstanding, Basic 21.2M shares +0.6%
Weighted Average Number of Shares Outstanding, Diluted 21.2M shares +0.6%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 72M USD -10.7%
Research and Development Expense 137M USD -15.6%
General and Administrative Expense 58M USD +12.2%
Costs and Expenses 195M USD -8.88%
Operating Income (Loss) -123M USD +7.78%
Nonoperating Income (Expense) 4.75M USD -12.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -118M USD +7.56%
Income Tax Expense (Benefit) -2.79M USD -165%
Net Income (Loss) Attributable to Parent -115M USD +12.7%
Earnings Per Share, Basic -5.46 USD/shares +13.5%
Earnings Per Share, Diluted -5.46 USD/shares +13.5%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 35.8M USD -62.4%
Accounts Receivable, after Allowance for Credit Loss, Current 8.18M USD -56.7%
Assets, Current 287M USD -36.1%
Property, Plant and Equipment, Net 25.1M USD +109%
Operating Lease, Right-of-Use Asset 41.2M USD +71.9%
Other Assets, Noncurrent 105K USD -87.3%
Assets 399M USD -19.5%
Accounts Payable, Current 10.7M USD +34.6%
Employee-related Liabilities, Current 4.79M USD -4.73%
Accrued Liabilities, Current 12.8M USD -29.5%
Liabilities, Current 58.2M USD -14.6%
Operating Lease, Liability, Noncurrent 48.1M USD +116%
Other Liabilities, Noncurrent 227K USD -46.7%
Liabilities 250M USD -2.89%
Accumulated Other Comprehensive Income (Loss), Net of Tax -653K USD +56.6%
Retained Earnings (Accumulated Deficit) -294M USD -64.5%
Stockholders' Equity Attributable to Parent 149M USD -37.4%
Liabilities and Equity 399M USD -19.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -25M USD +29.9%
Net Cash Provided by (Used in) Financing Activities -7.35M USD -2542%
Net Cash Provided by (Used in) Investing Activities -13.1M USD -139%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 21.2M shares +0.6%
Common Stock, Par or Stated Value Per Share 0.01 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -45.5M USD -2467%
Interest Paid, Excluding Capitalized Interest, Operating Activities 3.14M USD
Deferred Tax Assets, Valuation Allowance 115M USD +70%
Deferred Tax Assets, Gross 123M USD +66.5%
Operating Lease, Liability 50.6M USD
Payments to Acquire Property, Plant, and Equipment 787K USD -75.1%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -114M USD +11.9%
Lessee, Operating Lease, Liability, to be Paid 95.3M USD
Property, Plant and Equipment, Gross 50.3M USD
Operating Lease, Liability, Current 2.43M USD -54.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 8.22M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.75M USD
Operating Lease, Weighted Average Discount Rate, Percent 0.07 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.8M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 8.47M USD
Deferred Tax Assets, Operating Loss Carryforwards 43K USD -99.9%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 1.06M USD +367%
Lessee, Operating Lease, Liability, to be Paid, Year Four 8.72M USD
Operating Lease, Payments 76.5K USD
Deferred Tax Assets, Net of Valuation Allowance 7.56M USD +26.6%
Share-based Payment Arrangement, Expense 25.8M USD -8.97%
Interest Expense 2.36M USD +17.9%
Preferred Stock, Par or Stated Value Per Share 0.01 USD/shares 0%